Menopur (Menotrophin)

Menotropin provides both follicle‑stimulating hormone (FSH) and luteinising hormone (LH) activity. The FSH component binds to receptors on granulosa cells, promoting follicle growth and estrogen synthesis, while the LH component activates receptors on theca cells and mature follicles, supporting androgen production and final maturation leading to ovulation.

The dose of Menopur is individualized; a prescribing clinician determines the amount and schedule based on the patient’s ovarian response, body weight, and treatment protocol. Dosing may be adjusted during the stimulation cycle according to monitoring of follicular development and hormone levels.

Menopur is intended for use before conception to induce ovulation; its safety in established pregnancy has not been established, and it is generally not recommended during pregnancy. Limited data are available for breastfeeding, so the medication should be avoided unless the benefits outweigh potential risks as assessed by a healthcare professional.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Menopur differs from recombinant FSH products by containing a natural mixture of FSH and LH activity, which can be advantageous in patients who require both hormones for optimal follicular development. Compared with pure FSH preparations, Menopur may reduce the need for separate LH supplementation, but individual response varies and treatment choice should be guided by clinical assessment.

Menopur powder for injection must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until reconstitution, and any unused portion should be discarded according to local regulations after the recommended storage period.

Menopur is supplied as a sterile powder that is reconstituted with a suitable diluent to create a solution for injection. The solution is administered by subcutaneous or intramuscular injection, typically once daily, under the supervision of a fertility specialist who provides instructions on injection technique and timing relative to the treatment cycle.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, rapid weight gain, and, in severe cases, thromboembolic events or renal failure; severe allergic reactions such as anaphylaxis; and the possibility of multiple pregnancy. Patients should be monitored closely for early signs of these complications.

Menopur is contraindicated in women with known hypersensitivity to menotropin or any excipients, uncontrolled thyroid disease, active ovarian cysts, ovarian tumors, or severe endometriosis. It should also be avoided in patients with uncontrolled hypertension, recent thromboembolic events, or those who are pregnant or breastfeeding unless specifically advised by a physician.